Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 17,253 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase 2 Study Clear all
Recruiting Phase 2 Interventional

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

NCT06710288
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Gemcitabine, N-803, M-CENK
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed No phase listed Observational

Computer-based Screening for Diabetic Retinopathy

NCT01614327
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
VisionQuest Biomedical LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
19,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

NCT03394027
View directory record Official record
Conditions
Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
Interventions
ONC201
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 22, 2026, 10:34 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

NCT03241186
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Robert R. McWilliams, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Jacksonville, Florida • Iowa City, Iowa • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

NCT03407170
View directory record Official record
Conditions
Advanced Melanoma
Interventions
pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
balicatib (AAE581)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Timeline
Started 2004
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03487276
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
IFX-1, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Fort Myers, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 22, 2026, 10:34 PM EDT
Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Emavusertib, Venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

NCT00526591
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, conventional surgery
Drug · Procedure
Lead sponsor
Jorge A. Garcia, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

NCT06572618
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

NCT01692197
View directory record Official record
Conditions
Leukemia
Interventions
E7070, Idarubicin, Cytarabine, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597
View directory record Official record
Conditions
Covid19
Interventions
BGE-175, Placebo
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
50 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Mesa, Arizona • Chula Vista, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT05613413
View directory record Official record
Conditions
Metastatic Squamous Non-Small Cell Lung Carcinoma
Interventions
Pacliltaxel or Nab-paclitaxel, Carboplatin or Cisplatin, Pembrolizumab, Cabozantinib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Active, not recruiting Phase 2 Interventional

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

NCT01424982
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ponatinib, Ponatinib Hydrochloride, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

NCT01689623
View directory record Official record
Conditions
Healthy Participants
Interventions
TMC435, Atorvastatin, Simvastatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

NCT00400803
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Gemcitabine, Carboplatin, Bevacizumab
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01829503
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine and cytarabine, Supportive Care
Drug · Other
Lead sponsor
Annie Im, M.D.
Other
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 22, 2026, 10:34 PM EDT
Withdrawn Phase 2 Interventional

A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

NCT01524068
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard Steroid Treatment, The Standard Steroid Treatment, Plasma Exchange and rituximab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

NCT00684060
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

NCT00103324
View directory record Official record
Conditions
Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

NCT02539459
View directory record Official record
Conditions
Sporadic Angiomyolipomas (AMLs)
Interventions
Everolimus
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Exercise and NutraStem (NT-020): Effects on Stem Cells

NCT01847027
View directory record Official record
Conditions
Adult Stem Cell Proliferation
Interventions
NutraStem, Placebo
Drug
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00881361
View directory record Official record
Conditions
Breast Cancer
Interventions
systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 10:34 PM EDT